Skip to main content

FNLCR Acquisitions Beta.SAM.gov Notices

All formal announcements concerning all contract competition (including FNLCR) will be announced at minimum, to beta.SAM.gov. Information posted to beta.SAM.gov takes precedence over information provided on this website. Please be advised this website does not serve as the government's official government-wide point of entry (GPE).

Beta.SAM.Gov Notices

 

November 19, 2020

Type: Special Notice (Original)

Notice Number: HHS-NIH-NCI-RFI-MOSB-75N91020R00062-1

Title: Request for Information (RFI) for the National Cancer Institute’s Federally Funded Research and Development Center (FFRDC)/Frederick National Laboratory for Cancer Research (FNLCR)

 


September 11, 2020

Type: Special Notice (Original)

Notice Number: 75N91020R00062 

Title: Special Notice Announcing Re-competition of the National Cancer Institute’s (NCI) Federally Funded Research and Development Center (FFRDC) Contract 

 


September 11, 2020

Type: Special Notice (Original)

Notice Number: HHS-NIH-NCI-SNupdate-MOSB-0000-42-1 

Title: Update on the Re-Competition of the National Cancer Institute’s Federally Funded Research and Development Center (FFRDC) contract. 


 

January 17, 2017

Type: Special Notice (amendment)

Notice Number: HHS-NIH-NCI-SNupdate-MOSB-0000-42

Title: Update on the Re-Competition of Operations and Technical Support for the National Cancer Institute's Federally Funded Research and Development Center (FFRDC)/Frederick National Laboratory for Cancer Research (FNLCR)


 

All Updates

 

September 14, 2020

On September 11, 2020, the Government posted a Special Notice ending the prior competition, Notice Number: HHS-NIH-NCI-SNupdate-MOSB-0000-42-1 entitled, "Update on the Re-Competition of the National Cancer Institute’s Federally Funded Research and Development Center (FFRDC) contract", and posted a Special notice opening the new competition, Notice Number: 75N91020R00062 entitled "Special Notice Announcing Re-competition of the National Cancer Institute’s (NCI) Federally Funded Research and Development Center (FFRDC) Contract"

 


January 17, 2017

To provide clarification to the Amendment posted to FedBizOpps Announcement: HHS-NIH-NCI-SNupdate-MOSB-0000-42, the Government is providing the following additional information to the public.

On 30 Sep 2016, the NCI announced a suspension of the re-competition of the FFRDC contract. NCI halted its re-competition process for a deliberative assessment of its acquisition planning approach.

Since the re-competition was announced on May 27, 2015, there have been a number of significant developments for the mission of the National Cancer Institute affecting the work the FFRDC performs on behalf of NCI and other NIH institutes.

For example, the FFRDC has been rapidly responding to emerging health crises, including Ebola and Zika. The FFRDC was tasked with producing an experimental Zika vaccine for clinical trial use, a process expected to continue through the 2017 calendar year.

In December 2016, President Obama signed into law the 21st Century Cures Act, which includes the Beau Biden Cancer Moonshot℠ (Cancer Moonshot). The new law authorizes $1.8 billion over seven fiscal years, beginning with FY17, for Cancer Moonshot. Another bill, also signed into law in December 2016, appropriated the first $300 million for this purpose.

NCI is carefully evaluating the ways in which Cancer Moonshot and other developments will affect how the FFRDC is mobilized and responsive to these urgent, national priorities. To that end, FFRDC operations are moving forward with a short-term, sole source contract with Leidos Biomedical Research, Inc., for one year, which can be extended one year at a time up to a total of five years. The Government plans to resume the re-competition process for a long-term FFRDC contract upon award of this sole source contract, ensuring the follow-on requirement is executed using full and open competition to the fullest extent possible.


October 07, 2016

To provide clarification to the Amendment posted to FedBizOpps Announcement: HHS-NIH-NCI-SNupdate-MOSB-0000-42, the Government is providing the following additional information to the public.

In 1972, the Frederick Cancer Research Center (FCRC) began operations under the authority of The National Cancer Act of 1971. The National Science Foundation (NSF) notified the National Institutes of Health (NIH) that the FCRC was officially designated as a Federally Funded Research and Development Center (FFRDC) in 1975. Now known as the Frederick National Laboratory for Cancer Research (FNLCR), the FFRDC is sponsored by the NIH through the National Cancer Institute (NCI). NCI manages, administers, monitors, funds, and is responsible for the overall use of the FFRDC. 

In May of 2016, NIH approved the continued sponsorship of the FFRDC mission for an additional 5 years, through May 2021, in accordance with Federal Acquisition Regulations (FAR) governing FFRDC operations. This 5-year periodic review is required for all FFRDCs to ascertain the need for on-going research and comprehensively determine if that need continues to exist. All previous determinations to continue the sponsorship of the FFRDC have been approved since the FFRDC came into existence in 1975.

The present contract to operate the lab runs through Sept. 25, 2018. On 30 Sep 2016, the NCI announced a suspension of the re-competition of the FFRDC contract. NCI has halted the re-competition process for a deliberative assessment of its acquisition planning approach. Further information will be posted to FedBizOpps as it becomes available, but the operations of the lab will continue unabated and the contract re-competition will resume at a later date.   

  • Updated: